Why CBD Stocks are Rising Stars (YCBD, MJNA, CBGL, CBDD, CWBHF) – MMJObserver | Medical Marijuana, Cannabis, & Hemp News – MMJ Observer

With all the hoopla over the cannabis market, its younger brother is a more promising star: CBD. The CBD market wins over the cannabis market because it doesn’t have any hurdles to jump – that means legal or cultural – on its way to billions in total global sales. It just needs greater visibility.

Cannabis is expected to grow by leaps and bounds, but it suffers from both legal and cultural pushback. It isn’t just about legality here. Decades of disinformation and legacy norm boundaries have dealt cannabis a heavy toll in the PR department, and that ground isn’t easy to make up in a hurry.

But none of that exists in any important way for CBD because all of that is really about THC. Furthermore, there are other “innocent” cannabinoids to talk about next, including CBG, CBN, THCV, CBDA, etc. Each can get in line for its own coming out party over coming years.

But the winner right now, according to experts and analysts, is CBD. One recent piece of research (May 2020, Industryresearch.biz) for strictly CBD oil shows growth expectations at a CAGR of roughly 32.0% over the next five years, to reach over $1.25 billion by 2024, up from $311.8 million in 2019. These numbers are smaller simply because this is the market for CBD by itself. The market for CBD-based products is much larger, and will grow to be many times this size over the same period, with analysts calling for $15-25 billion in sales by 2025. Grand View Research, for example, puts the global cannabidiol-based products market at a value of $4.6 billion already by 2018. Their research suggests it will grow by over 22% CAGR from 2019 to 2025 to reach nearly $19 billion.

With that in mind, we take a look at a selection of active CBD stocks, including cbdMD Inc (NYSEAMERICAN:YCBD), Medical Marijuana Inc (OTCMKTS:MJNA), Cannabis Global Inc (OTCMKTS:CBGL), CBD of Denver Inc (OTCMKTS:CBDD), and Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF).

cbdMD Inc (NYSEAMERICAN:YCBD) owns and operates the consumer hemp-based CBD brand, cbdMD. The company’s product categories include CBD tinctures, capsules, gummies, bath bombs, topical creams, and animal treats and oils.

It also offers pet related CBD products under the Paw CBD brand name. The company distributes its products through an e-commerce Website, wholesalers, and various brick and mortar retailers in the United States.

cbdMD Inc (NYSEAMERICAN:YCBD) just announced that its pet CBD brand, Paw CBD, has seen an approximate 64% increase in net sales from its March 2020 quarter of approximately $750,000 to approximately $1,229,000 for its June 2020 quarter.

“Paw CBD was launched less than one year ago, and now it is one of America’s leading CBD pet brands,” said Ken Cohn, CMO of cbdMD, Inc. “Sales metrics are all moving in the right direction, with Paw CBD now trending at over a $7mm annualized run rate, and cbdMD’s overall direct-to-consumer (DTC) sales making up over 70% of the brand’s revenue. We are seeing the DTC power of cbdMD.com translating into significant growth for PawCBD.com.”

The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 11% in that timeframe. Shares of the stock have powered higher over the past month, rallying roughly 54% in that time on strong overall action.

cbdMD Inc (NYSEAMERICAN:YCBD) pulled in sales of $9.4M in its last reported quarterly financials, representing top line growth of 65.7%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($14.9M against $5.8M).

Medical Marijuana Inc (OTCMKTS:MJNA) bills itself as an investment holding company that operates in the medical marijuana and industrial hemp markets, including CBD products. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company licenses its proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal cannabinoid industry.

It engages in the research and development of cannabinoid-based pharmaceuticals; and marketing and distribution of cannabidiol hemp oil-based products. In addition, the company provides management support and services to cooperatives, collectives, health and wellness facilities, and medical clinics, and consulting and securities services to businesses and individuals in the legal cannabis industry.

Medical Marijuana Inc (OTCMKTS:MJNA) just recently announced that its subsidiary Kannaway is proud to support the European Industrial Hemp Association (EIHA) in its recent opinion letter to the European Commission on the legal status of cannabidiol (CBD) and hemp.

EIHA’s letter was written in response to the European Commission’s decision to suspend all applications for hemp extracts and natural cannabinoids under the European Union’s Novel Food rules and also deem under a “preliminary conclusion” that extracts from the flowering and fruiting tops of the hemp plant should be considered a drug under the United Nations Single Convention on Narcotic Drugs of 1961. EIHA explains that the decision is “not based on the latest scientific literature nor inspired by the current debate at the United Nations level.”

Even in light of this news, MJNA has had a rough past week of trading action, with shares sinking something like -5% in that time. That said, chart support is nearby, and we may be in the process of constructing a nice setup for some movement back the other way. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -13%.

Medical Marijuana Inc (OTCMKTS:MJNA) managed to rope in revenues totaling $13.4M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of -34%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($5M against $11.1M, respectively).

Cannabis Global Inc (OTCMKTS:CBGL) is one of the most interesting and possibly undervalued names in the space given its strong IP backing – with more than a half dozen provisional patents in process at the USPTO – and its innovative movement toward non-CBD cannabinoid production technology, suggesting the company will be at the vanguard of any move to establish the more exotic cannabinoids as commercial-scale markets.

One of the key moves made recently by the company is its venture into the alcohol substitute mixing space. According to its recent release, Hemp You Can Feel™ mixers are now available for online consumer purchase as well as bulk purchase for wholesale distribution. Cocktails based on the Hemp You Can Feel™ mixers provide an experience on par with light alcohol consumption, but without any of the harmful side effects of alcohol.

“Because of the ultra-low levels of hemp extracts utilized, we feel we set a new standard for product-safety and satisfaction in the hemp food and beverage category with this product,” commented Arman Tabatabaei, CEO of Cannabis Global. “While our Hemp You Can Feel™ beverages likely have the lowest hemp extract levels in the industry, we believe we provide a vastly superior positive effect upon use. We invite all consumers and alcohol industry participants to try what we see as the first viable alternative to alcoholic beverages. Our website is www.HempYouCanFeel.com. Take the HempYouCanFeel Challenge!”

Cannabis Global Inc (OTCMKTS:CBGL) believes the use of Hemp You Can Feel™ is significantly safer than the consumption of other hemp-based or high-cannabidiol (CBD) based beverages. Because of the natural water solubility of the preparations, only a minuscule amount of hemp extracts is present in the cocktail mixers. Laboratory analysis and results by High Performance Liquid Chromatography (HPLC) indicated the presence of hemp extracts in the non-detectable category.

Shares of CBGL are testing key support in recent action, and have a history of sharp runs off of support when challenged. We would also note that the company has been get more and more catalysts out in the public eye in recent weeks suggesting that something new and positive is usually on the way to fuel the next move.

Cannabis Global Inc (OTCMKTS:CBGL) had no reported sales in its last quarterly financial data. But it appears to be closing in on commercial-stage operational gains for shareholders and has a strong IP edge in the industry.

CBD of Denver Inc. (OTCMKTS:CBDD) is another less well-known name making strong strides in the space. The company engages in developing and commercializing cannabidiol (CBD) products. It is involved in the research, development, and distribution of premium hemp extract products. CBD of Denver Inc. operates as a subsidiary of Swiss Industry Ventures AG. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for shareholders.

CBDD offers a superior CBD product that is full spectrum without depending on THC to activate the benefits of the cannabidiol. According to company materials, CBDD was created to offer the consumer a unique and new perspective on the unorganized and confusing CBD industry. CBD of Denver, Inc. is the only company to release a comprehensive CBD Social Network (www.cbdsocialnetwork.com). The idea of the network is to connect CBD users from America and around the world to interact and discuss CBD uses, treatments and products. The site has been active for 3 months and already receives 2000-2500 hits a day.

CBD of Denver Inc. (OTCMKTS:CBDD) just put out a recent announcement providing additional information on the revenue reported for Rockflowr, GmbH and CBD Welt 24, GmbH.

According to the release, revenue for Rockflowr and CBD Welt 24, subsidiaries of CBD of Denver, Inc., was reported in CBDD’s 2nd Quarter Disclosure with OTC Markets as of the date each company was acquired and not for their own full quarter. To provide context for the revenue numbers reported in CBDD’s quarterly statement, CBBD is providing the revenue generated by Rockflowr and CBD Welt24 for their full quarters and not just since they were acquired by CBDD in the middle of quarter.

Rockflower: For the period from April 1, 2020 through June 30, 2020 Rockflowr had revenue of 1,710,000.00 CHF or approximately $1,833,120.00 USD with net profits of 131,089 CHF or approximately $140,527 USD. CBD Welt 24: For the period from April 1, 2020 through June 30, 2020 CBD Welt24 had revenue of 56,500.00 CHF or approximately $60,568,00 with a net profit 45,416 CHF of approximately $48,686 USD.  This amount only reflects revenue after the first harvest as it took two months from initial planting until first harvest to generate revenue.  Moving forward, CBD Welt24 expects a harvest every month that should substantially increase revenue.

CBD of Denver Inc. (OTCMKTS:CBDD) just posted a net profit in Q2, which is the first time in the company’s history that it has achieved that milestone, which the company rightly sees as an indication of being on the right course in terms of providing value for its shareholders.

Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) develops and distributes hemp-based cannabidiol (CBD) wellness products. Its products include CBD hemp oils, capsules, topicals, and pet products that feature CBD hemp oil extracts. Charlotte’s Web Holdings, Inc. sells its products online as well as through distributors, and brick and mortar retailers.

Charlotte’s Web Holdings, Inc. is a market leader in the production and distribution of innovative hemp-based cannabidiol wellness products. Founded by the Stanley Brothers, the Company’s premium quality products start with proprietary hemp genetics that are responsibly manufactured into whole plant hemp extracts naturally containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids and other beneficial hemp compounds. Industrial hemp products are non-intoxicating.

Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) recently announced its “Trust The Earth” initiative, which is designed to democratize access to hemp-derived products for those seeking wellness and relief.

Studio Number One, a creative agency co-founded by artist Shepard Fairey, created the original artwork, first publicly exhibited by Charlotte’s Web as a mural in Brooklyn in October 2019.  Today, Studio Number One’s original art is exhibited from the ground up, literally, as field art on a mammoth scale of 76-acres in America’s heartland.

Even in light of this news, CWBHF has had a rough past week of trading action, with shares sinking something like -5% in that time. That said, chart support is nearby, and we may be in the process of constructing a nice setup for some movement back the other way.

Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) pulled in sales of $28.9M in its last reported quarterly financials, representing top line growth of 0.1%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($75.5M against $42.2M).

This article is part of JournalTranscript.com Networks. Read the JournalTranscript.com Networks Disclaimer.

U.S. CBD maker CV Sciences records $4.7 million loss in 2nd quarter – HempToday

Share this:
  •  
  •  
  •  
  •  
  •  

U.S.-based CBD maker CV Sciences said it had operating losses of $4.7 million in the second quarter of 2020, a $6 million swing compared to second quarter profits of $1.3 million in 2019. Revenues fell to $5.4 million in the period, plunging 68% from $16.9 million recorded in the second quarter of last year, the San Diego-based company said in an earnings report. The revenue is also a decrease from the $8.3 million CV Sciences reported in the year’s first quarter ending March 31.

CV Sciences shares are down from a 12-month high of $3.81 on ‎Aug. 22, 2019.

The company attributed the losses, in part, to the COVID-19 pandemic.

‘Challenging’

“We continue to effectively navigate the challenging industry and COVID-19 environment by controlling costs and accelerating new product and category development, while continuing to drive distribution growth,” CEO Joseph Dowling said. CV Sciences products are now in 6,325 stores in the USA, up from 5,799 at the end of the first quarter of 2020, according to the report.

“We remain highly confident in the long-term outlook for the hemp-derived CBD category and will continue to position ourselves for the future of CBD as the regulatory environment continues to develop,” Dowling said.

New product launches

CV Sciences also announced it has launched CVTM Acute, a formula that supports the immune system and respiratory health, and Happy Lane, a THC-free CBD brand it will market in convenience stores.

CV Sciences did $2.0 million in online sales during the second quarter, and reported its cash balance as $8.1 million.

Share this:
  •  
  •  
  •  
  •  
  •  

Does CBD Oil Have an Expiration Date? – Plants Before Pills

If you haven’t tried CBD for pain relief before, it might be just the treatment you need—whether for acute or chronic pain. Unlike THC, CBD is the compound in cannabis that promotes a relaxed feeling and natural pain reduction. It does not get users “high,” and it is not an addictive substance. The primary reason anyone should consider CBD for pain relief is to enjoy a fuller life without the dangerous side effects of pharmaceuticals.

Unlike opioids, CBD is not addictive and does not have dangerous side effects for the vast majority of users (of course, it is technically possible for someone to be allergic to just about anything, though this is very rare with CBD).

Even non-opioid painkillers can be dangerous, such as Tylenol, which can cause kidney damage when taken regularly. New-to-cannabis users should work with their doctor and a qualified dispensary in order to make sure they get the right CBD and dosage for their needs.

Some patients who are new to CBD might worry about having a “low tolerance” or building up a tolerance with CBD usage, but it seems that CBD works a little differently than other products that lead to tolerance.

Tolerance and CBD

Tolerance occurs when someone has to increase the use of a product in order to get the same, original effects. Tolerance is not indicative of dependence or addiction, both of which reference the compulsive use of a product. Tolerance also doesn’t mean a person “needs” a certain level to feel what they consider as normal.

It’s perfectly normal for tolerance to happen with just about anything, and it can stem from a variety of levels including cellular, metabolic, and behavioral. It’s well-known that people who take THC can build up a tolerance, and it sometimes occurs in an uneven manner based on each individual’s physiology.

THC tolerance occurs mostly at the cellular level. This is because THC binds to CB1 receptors in the brain. This binding happens over and over; the cells attempt to reverse the effect in order to achieve regular CB1 activity. These attempts are made via desensitization and internalization.

However, CBD tolerance doesn’t work like this and some studies show CBD does not lead to an increased tolerance. Plus, CBD affects the endocannabinoid system differently than THC, which further reduces the odds of tolerance. This means that a new cannabis user who exclusively uses CBD won’t have the “best” results the first few times they use it. Instead, they can enjoy all the benefits of CBD for pain relief without ever worrying about building up a tolerance and having to use (and spend) more.

Maximizing Cannabis for Pain Relief

Combining cannabis with other natural, non-addictive options for pain relief can maximize the benefits. One of the most common pairings with CBD is kratom, which is derived from a tree located mostly in Southeast Asia. Many people say that the effects of kratom are similar to the “good” effects of opioids (such as mild relaxation and pain relief) without the same risk of addiction or dangerous side effects.

In decades past, kratom used to be chewed, was used in cooking, or was brewed in tea. However, today it’s usually in pill form or crushed to be smoked. Even though kratom is not an opioid, it’s still considered a controlled substance, so it’s important to follow kratom capsule storage best practices if you have children in the home.

Kratom is mostly used for pain management in the western world today, but it also has various effects depending on the dosage. For example, very low doses actually increase energy, and some people use kratom in lieu of coffee.

Pain Management for Life

A primary reason many new cannabis users seek out both CBD and kratom is because they are rightly concerned about the risks and long-lasting effects of pharmaceutical medications. Everyone will experience pain at some point in their life. In fact, back pain is the leading cause of disabilities in the U.S. and around the world.

Pain can get in the way of your daily life, prevent you from working, stop you from hobbies you enjoy, and generally reduce the quality of your life. With chronic pain especially, which is common with back pain, you need and deserve a treatment that will work for life. Taking pharmaceuticals such as opioids is simply not an option for long-term use.

For those who have never tried any form of cannabis product before, you’re living in an unprecedented era where you have legal access to guaranteed products that are high quality and safe. Working with your doctor and a recommended dispensary will ensure you get the right CBD products for you, and you can always try various strains to test the results. Many dispensaries also offer kratom, and you can get advice from an expert on how to use the two alternatively or in tandem.

Just because a lot of people have pain, or you’ve been dealing with it for a long time, doesn’t make it “normal.” You can reclaim your life without unnecessary risks by exploring the vast world of CBD products and kratom. Those who are new to cannabis are pleasantly surprised by how accessible pain relief can be without needing to depend on costly or high-risk medications, and they find that CBD and like products can easily integrate into any lifestyle.

iHemp Hour Aug. 13 – Delta-8 THC, Types Of CBD Oil Products – mitechnews.com

ANN ARBOR – iHemp Hour July 16 featured what’s happening with the US Hemp Authority Certification Program and Transparency in Hemp Supply Chain.

Guests included: Certification Programs, Marielle Weintraub, PhD, U.S. Hemp Authority President. And for transparency in the Hemp Supply Chain, Dr. Richard McDermott and Terri Miller of Signakey.

On iHemp Hour Aug. 13, Hemp farmers will learn about Delta-8 THC, types of CBD oil products that are selling and how to setup white label products with your hemp or oil.

Nick Young of Krystilion spoke at the Midwest iHemp Expo in January about hemp processing. Their processing business is rapidly growing and they are entering new territory in cannabinoid production with their work with Delta-8.

TGA Approves Record Number Of Medical Cannabis Applications – HempGazette

TGA Australia and medical cannabis

Australia’s Therapeutic Goods Administration (TGA) had a busy July in relation to approving applications for medicinal cannabis products.

Australia’s Special Access Scheme (SAS) enables suitably authorised health practitioners to access therapeutic products not included in the Australian Register of Therapeutic Goods (ARTG). The only cannabis product currently included in the ARTG is Sativex (nabiximols), which contains THC (tetrahydrocannabinol) and CBD (cannabidiol).

There are several different pathways to gaining approval for cannabis medications through the SAS – categories A, B and C. Medical cannabis applications are generally via the Category B pathway.

Up to 31 July 2020, the TGA had approved more than 56,000 SAS Category B applications for unapproved medicinal cannabis products. That number is a cumulative figure over a very long period of time – since 1992, so nearly 30 years.

Approval numbers have certainly picked up in the last year or so. Updated figures from the TGA indicate 5,564 approvals were issued last month, so nearly 10% of all approvals ever made under SAS Category B occurred in July this year. July’s figures were well up on June’s (4,630) and more than double July last year (2,207).

What’s not clear from the figures are the numbers of different types of medicinal cannabis products are being approved, but the chances are in many cases these are cannabidiol-based.

It’s quite possible the TGA could have less workload (and doctors/patients less hassle) in this respect reasonably soon.

Back in April, the TGA commenced a consultation on altering the Schedule 4 listing for cannabidiol and adding  a new entry that would see some CBD preparations available without a prescription from pharmacies. An initial decision will be made public next month, followed by another consultation period and then public notice of a final decision on November 25 this year.

The thousands of applications currently being approved by the TGA each month only covers the tip of demand for medicinal cannabis in Australia. Last month we mentioned a survey report stating just 3.9% of Australians who used cannabis for medical purposes obtained it by prescription. Another recently released study put the figure even lower, finding just 2.7 per cent were accessing legal products.

Dizzy Wright & Demrick On Their Cannabis Businesses, New Album: ‘We Want To Change The Narrative’ – Forbes

Dizzy Wright & Demrick

Dizzy Wright & Demrick

Courtesy Photo

As the 2020 summer-in-quarantine rolled out, Dizzy Wright & Demrick dropped their second cannabis-themed album, “BLAZE WITH US 2.” The release was celebrated in Dizzy’s clothing store, Still Movin, in Las Vegas.

The album was released and distributed by JohnnyShipes, Shieistbubz and Smoke DZA’s Smoker’s Club Records via Cinematic Music Group. The second installment of the west coast duo’s series (the first racked up over 20 million streams on Spotify alone) is bolder, more musical, and as eclectic as it gets, touching on reggae, old school hip hop, trap, and more.

In addition, the album features skits by legendary Tommy Chong, who makes a few guest appearances on the album, which were recorded while smoking with the rappers in the studio.

Seeking to better understand the album, their motivations, and their numerous business ventures, I spent some quality time with Dizzy and Demrick on a Zoom call – in a responsible COVID-19 fashion.

Recommended For You

“We want to change the narrative of weed raps,” explains Dizzy. “We wanted to be the thinkers and we wanted to create the weed music that had the substance in it, that kind of represents the conversations we have, and also the growth that we’re having in the cannabis industry.”

Reminiscing about the recording of the first “Blaze With Us” album, Dizzy points out how cannabis was not legal in many of the places it is nowadays. “We were really, really pushing for it to be legal. Now we’re pushing for it to be federally legal,” he says. “And we’re also celebrating the wins that we’ve been having in the cannabis industry.”

For Demrick, it’s all about getting the right messages across: “There’s a lot of knowledge and information that’s given out on that album.”

See also: Chris Webby Talks Cannabis, Psychedelics, Rap And Business: ‘Everything Is Connected’

And, with it being the first official LP out of The Smokers Club, the stakes were high, adds Matt Van Sol, project manager for The Smoker’s Club and Cinematic Music Group. Van Sol was under double the pressure, he says, being this his first time managing an artist project for Cinematic.

Fortunately, the results have been highly pleasing so far.

“The team, including Chris Herche, Mike Epstien and Ernest Noel, works extremely hard and Smoker’s Club Records will be a household name before you know it,” he continues, touting “Blaze With Us 2” as the perfect project for their debut. “The whole album is a vibe and the production is crazy, all 15 tracks definitely represent our culture at The Smoker’s Club. It’s definitely one of the best hip-hop albums of the summer.”

Two Gifted Lyricists

Dizzy and Demrick like to think of themselves as “a pair forged in the tradition of West Coast hip hop.”

­Dizzy was an XXL Freshman; while Demrick was discovered by Kurrupt in housing projects in Philly, who flew him out to LA, where he put in 10,000 hours writing alongside the cream of the crop, including Cypress Hill and Xzibit, got to freestyle for Dr. Dre, and ended up on cuts and tours with Berner, Logic, AD and others.

Being cannabis aficionados, Dizzy and Demrick are always in touch with the latest developments in the industry and the culture. In fact, both rappers have created award-winning cannabis strains like Dizzy OG (Crown Genetics) and Demrick’s Gas-Lato (GasCo).

Dizzy and Demrick recorded the first “BLAZE WITH US” album in 2016.

“It was really just organic vibes,” says Dizzy, visibly rolling a blunt on camera. “Just getting in the studio and vibing off of each other, just seeing what we can come up with together. This one [Blaze With Us 2] was a little more thought out.”

While the process was basically the same, the duo went into the studio knowing they wanted to “elevate the sound,” in relation to their prior recording.

Dizzy Wright & Demrick

Dizzy Wright & Demrick

Courtesy Photo

This time, they were after versatility, really showing their chemistry “by going back and forth on certain songs and things like that.”

The ultimate intent was to make them sound like a group, and not just two rappers randomly collaborating. And, damn, did they do it. From the very beginning, the album is heavily reminiscent of Eric B. and Rakim

“We definitely were strategic about being versatile, and I hope it came off like that,” Dizzy adds.

At the same time -Demrick jumps in- this was all very organic. It came up while touring and chilling with friends, looking for cannabis-friendly refuge as they drove across a country where cannabis is not legal in many states.

See also: DAMN: The Cannabis-Infused Show That Feeds Latin America’s Hip-Hop Culture

“We started making the music… inspired by Red, Meth, [Redman and Method Man]… They were solo artists, and they came together and created this special moment.”

The Tommy Chong Skits

As mentioned above, Tommy Chong was also involved in this stoner favorite.

“We had a smokeout session,” Dizzy discloses. “We just got the kick it, hang out, smoke with him, and talk… pick his brain a little bit.”

Dizzy Wright & Demrick

Dizzy Wright & Demrick

Courtesy Photo

Only a few days after this conversation, I caught up with Tommy Chong, who said he’d had a lot of fun recording that day. While not really pertinent to this story, a colorful comment indeed.

From this hangout time, Dizzy and Demrick took some little moments, and embedded the conversation into the new album.

But meeting Tommy gave the rappers a lot more than a few hours of fun. As soon as they finished the meeting, they went right to the studio and created the song “Don’t Worry.”

See also: Magic Johnson Talks CBD: ‘I’m A Believer’

“We were really inspired by some of the things that he was telling us and we wanted to incorporate that into the music. And yeah, I hope it shows,” Dizzy says laughing.

Let’s Get Down To Business

Both Dizzy and Demrick are more than just cannabis consumers and pot loving rappers. They are canna-businessmen.

“Being a cannabis lover, basically, my whole life, it was only right that we participate in the business,” Demrick says. But it’s all about being real, he adds. You can’t just hop onto the green rush and expect to come up with superior products.

Among Demrick’s projects is a partnership with DJ Hoppa and KushCo.

“It started there with Stony Point and that’s on the rec [recreational cannabis] market in Las Vegas. So, you know, it’s a trip to walk into some of these dispensaries out here and see bud that you chose on the shelves for people to enjoy as much as you enjoy,” he says.

Dizzy Wright & Demrick

Dizzy Wright & Demrick

Courtesy Photo

Demrick also sells two cannabis strains in Southern California with GasCo. One of the strains was created to go along with the new “Blaze With Us” album.

Dizzy also has a weed strain of his own, Dizzy OG. It’s cultivated by Crown Genetics.

See also: Isiah Thomas Discusses His Journey From NBA Champion To Champagne To Cannabis

“I met them back in a day. I was just, to be honest, going to all the weed events being a weed lover myself… I would just pop up and show love,” he says. It was at one of these events where he connected with his partners to be.

The rapper is also teamed up with Redwood in Las Vegas, and offers six strains in that market.

“It’s all about doing it right,” Demrick adds, sharing some business advice for aspiring cannabis entrepreneurs. “I feel like the game is getting more and more tight knit, and big business is coming in. So, the originators, the people that have been doing this, have been a part of the culture for so long, the big dollars will try to box these people out… So, this is our moment. It’s our opportunity to do it on a higher level, where it’s in stores, where there’s branding.”

So, be innovative, come up with new ideas, new ways to serve customers and patients, he concludes. “Start small, build up, figure out what it takes to get a license, or if you can’t get one because you have to have millions of dollars to get one, that team up with, and bring value to somebody who has one. And then from there, you build together… This is a fresh market, it’s going to be around hopefully forever, so plan for the long-term.”

Stream the full “Blaze With Us 2” album below.

Continue reading: Mike Tyson Will Print (Yes, Print) Cannabis Beverages

Can CBD Provide Relief For Those Suffering From Drug Withdrawal? – South Florida Reporter

https://www.freepik.com/premium-photo/cannabis-essential-oil-container-with-cannabis-leaves-cannabis-seeds_5636888.htm#page=1&query=cbd&position=34

Opioid addiction has become a rampant problem throughout the United States. The opioid epidemic has killed tens of thousands of people, with more than 120 people dying each day after overdosing on opioids.

So many people stay addicted to opioids without seeking treatment because of the side effects of withdrawal. The good news is that there are products that can be used to minimize withdrawal symptoms. CBD has shown a lot of promise as a treatment for those suffering from drug withdrawal. Here’s what you need to know.

What Are Opioids?

Opioids are prescribed by doctors as a way to treat pain because they relax the body. Common prescription opioids include OxyContin, Vicodin, and Percocet.  While these drugs are extremely effective in treating chronic pain, they pose the risk of addiction and dependence.

In fact, one study found that 21 to 29 percent of people prescribed opioids for chronic pain misuse them, and 8 to 12 percent of patients develop an opioid use disorder.

The problem is that opioids are highly addictive, and once someone is dependent on an opioid, the withdrawal symptoms can be unbearable. Aide aside from cravings, those addicted to these drugs will experience whole body restlessness and sweating, as well as anxiety, and gastrointestinal issues.

Traditional Treatment Options for Opioid Addiction

Commonly, opioid addiction or opioid misuse is treated using prescription medications that work to ease the withdrawal symptoms and cravings. Those addicted to opioids are also advised to attend counseling, to include behavioral therapy, which can change the user’s behaviors and attitudes that cause them to misuse opioids.

There are also other options, such as peer support groups like Narcotics Anonymous. Talking with others who are also battling opioid addiction can be life-changing for some.

While these traditional options can be effective in helping someone who is addicted to opioids, research has shown that cannabidiol, better known as CBD, may be another option to consider.

What is CBD?

CBD is a chemical compound that naturally occurs in the cannabis and hemp plants. However, legal CBD products, such as those from Green Roads CBD, only contain CBD that’s extracted from hemp plants. This is because the hemp plant has a lower percentage of THC, which is the cannabinoid that has psychoactive effects.

While CBD won’t get you high or make you feel euphoric, it does offer a host of other benefits. Studies have shown that CBD is effective in:

  • Relieving chronic pain
  • Reducing stress and anxiety
  • Improving heart health
  • Protecting the brain

CBD may even be helpful in treating some of the most common medical conditions, including heart disease, diabetes, and certain forms of cancer.

So how does CBD offer all of these benefits? While there’s still much research to be done, it’s thought that CBD stimulates and interacts with receptors that are part of the body’s endocannabinoid system.

This system’s main purpose is to maintain homeostasis. It also plays a vital role in the central nervous system, which means it impacts stress, appetite, mood, memory, sleep, and other functions.

What Research Shows

There’s still a lot to learn about CBD, how it interacts with the body, and how it could be an effective treatment for those suffering from drug withdrawal. With that said, research conducted in the last few years has shown that CBD’s interaction with the endocannabinoid system may be greatly beneficial for those suffering from opioid dependence.

One study found that CBD helped those who struggled with anxiety and cravings caused by opioid withdrawal. Participants in the study were given 400 or 800mg of CBD once a day for three days.

The data collected found that CBD offered significant immediate effects when compared to the participants that were given a placebo. Those who were given CBD experienced reduced cravings and lower rates of anxiety. Not only were the positive impacts noted immediately, but the effects also lasted a week post-treatment.

This study suggests that CBD may be an effective treatment in helping those going through opiate withdrawal. CBD may be able to be used to reduce withdrawal symptoms while also improving the quality of life.

What Kind of CBD is Best for Drug Withdrawal?

CBD products are available in many different forms. This means that you’re more likely than not to find a product that meets your needs. While edibles, such as gummies, are definitely the most popular, other options include:

  • Tinctures
  • capsules
  • Vape pens
  • Topical products

Not only are CBD products available in different forms, but they’re also available in different strengths and different kinds of CBD. As CBDGrade’s review site shows, there are CBD products that offer dosages as small at 5mg, all the way up to 500mg, and even more.

When it comes to CBD products, there are three different types that can be used. Isolate, broad-spectrum, and full spectrum. CBD isolate is the purest form of CBD and contains none of the other compounds found in the hemp plant, including THC.

Broad-spectrum CBD contains many of the other compounds from the plant, with the exception of THC. Full-spectrum CBD contains everything found in the hemp plant, including trace amounts of THC.

So what kind of CBD is best for those suffering from drug withdrawal? While there’s more research to be done, full-spectrum, lab-tested CBD oil is likely to offer the best effects. This is because full-spectrum CBD contains all of the medicinal and therapeutic compounds found in the plant, including other cannabinoids, terpenes, flavonoids, and other elements.

It’s also critical to only use lab-tested CBD. This is CBD that has been analyzed and certified by a lab to meet certain purity and potency standards.

If you’re someone suffering from drug withdrawal, self-medicating can be dangerous, so it’s best to first discuss with a medical professional.

Hemp CBD Vs. Marijuana CBD: What’s The Difference? – Benzinga

This article was originally published on Hoban Law Group, and appears here with permission.

Cannabidiol (or “CBD” for short) has gained immense popularity on the market in the U.S. and beyond over the last several years. CBD is just one of the many naturally-occurring phytocannabinoids found in the cannabis plant. Unlike THC (tetrahydrocannabinol), which is typically associated with causing a “high” in its users, CBD is non-psychoactive, which means the compound does not typically cause a high or euphoric effect in the user when consumed.

CBD in Both Marijuana and Hemp

Generally speaking, CBD can be found in both marijuana and hemp. Marijuana and hemp are both considered “cannabis” under the law, but prior to Congress passing the Agricultural Improvement Act of 2018 (the “2018 Farm Bill”), which builds upon the Agricultural Act of 2014 (the “2014 Farm Bill”), the law did not distinguish between “marijuana” and “hemp.” Before this distinction was made, cannabis referred to both marijuana and hemp without any differentiation between the two.

Now, however, federal law expressly excludes “hemp” from the definition of “marijuana,” which means that cannabis with a THC concentration that does not exceed 0.3% is no longer viewed as “marijuana” under federal law. Instead, this class of cannabis is recognized as “hemp.”

The Difference Between Hemp CBD and Marijuana CBD

Accordingly, the difference between hemp CBD and marijuana CBD is dependent upon the levels of THC in the plant from which the CBD is derived. So, if the CBD is derived from cannabis with a concentration of 0.3% THC or less, the CBD is derived from hemp. But if the same compound is derived from cannabis with a concentration of more than 0.3% THC, the CBD is derived from marijuana.

Legally speaking, the difference between hemp CBD and marijuana CBD is based on the THC content of the plant. Practically speaking, however, the difference between hemp CBD and marijuana CBD is rooted in how these plants and products are regulated both federally and on the state level, which determines the regulations governing the cultivation, processing, manufacture, distribution and sale of such plants and products.

Unlike marijuana, hemp has been removed from the federal Controlled Substances Act, which means that hemp is no longer treated like marijuana under the law. Consequently, after passing both the 2014 and 2018 Farm Bills, the cultivation of hemp was legalized at the federal level. This federal legislation also generally protects the interstate transport of hemp and hemp products, which, in turn, is responsible for why you can find hemp-derived products for sale in numerous retail locations throughout the country today.

Marijuana, however, is still considered a “controlled substance” under federal law. This means that in order to cultivate, process, manufacture, distribute, sell and/or purchase or consume marijuana or marijuana-derived products (i.e., cannabis with a THC concentration that exceeds 0.3%), such as marijuana CBD products, state laws must permit these types of activities in contravention of federal law. In other words, marijuana does not enjoy the same federal protections as hemp now does pursuant to the passage of the 2014 and 2018 Farm Bills.

Federal Legalization of Hemp

Of course, with federal legalization of hemp comes federal regulation. For example, the Food & Drug Administration (“FDA”) does not generally regulate marijuana or marijuana-derived products, including those that contain CBD, because marijuana remains illegal at the federal level. However, the 2018 Farm Bill tasked the FDA with implementing a framework for hemp-derived cannabinoid products entering the stream of U.S. commerce while reiterating that the passage of the Farm Bills did not affect the Federal Food, Drug & Cosmetic Act (“FD&C Act”).

Accordingly, and in relying on select provisions of the FD&C Act, the FDA has opined on numerous occasions that CBD cannot be marketed as a dietary supplement or added as an ingredient to food and beverages sold to consumers. In addition, the FDA has emphasized that neither CBD nor any other cannabinoid has received “GRAS” (Generally Recognized As Safe) status to date, nor have such cannabinoids been the subject of an approved food additive petition or a New Dietary Ingredient (“NDI”) notification submitted to the FDA. Additionally, the FDA has initiated enforcement actions against hemp-derived CBD products marketed as “drugs” to the public (i.e., with statements indicating the product may affect the structure or function of the human body, or is intended to diagnose, treat, cure or prevent any disease).

So, what does this all mean?

On a practical level, this means that the cultivation, processing, manufacturing and sale of hemp and marijuana (and products derived therefrom) are subject to vastly different regulations due to the distinctions under federal law between hemp and marijuana.

If you have questions about how to cultivate, process, manufacture, distribute or sell either hemp-derived or marijuana-derived products containing CBD in compliance with applicable laws, our attorneys at HLG are here to help.

Please contact our office today for a consultation!

Read the original Article on Hoban Law Group
Benzinga‚s Related Links:

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Benzinga Virtual Cannabis Conference Aug. 18 – mitechnews.com

ANN ARBOR – Benzinga VP Patrick Lane provides all the details about the BZCannabis Virtual Conference scheduled for Aug. 18. The event is free to watch and learn about how far the cannabis sector has come in Michigan since it became legal in 2019.

The premier gathering of cannabis entrepreneurs and investors in North America. No other conference offers the level of access and seamless interaction between entrepreneurs building future billion-dollar cannabis enterprises and the investors whose capital will make that happen.

WHO ATTENDS?

  • Investors

    Come face-to-face (virtually) with top cannabis
    companies to hear about their
    advancements in the rapidly
    changing space.REGISTER

  • Cannabis Executives

    Find new opportunities to
    grow business enterprises with
    lightning round presentations
    and 1:1 meetings.REGISTER

  • Traders

    Learn about the various companies
    making moves in the cannabis industry and
    hear live presentations from
    top cannabis CEOsREGISTER